Protected: FDA grants accelerated approval for Jemperli in endometrial cancer – GSK
There is no excerpt because this is a protected post.
There is no excerpt because this is a protected post.
Cycling at moderate intensity during dialysis could drastically improve the heart health of patients with kidney failure and result in significant savings for the NHS, according to new… read more.
FibroGen, Inc. has provided clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase III program for the treatment of anemia of chronic… read more.
As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.
GW Pharmaceuticals plc , a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for… read more.
AstraZeneca and FibroGen, Inc. announced that the FDA informed FibroGen that it will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the new… read more.
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of… read more.
In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with… read more.
Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer. The combination also improved progression-free survival… read more.
Bacteria or viruses like influenza that cause pneumonia can spread across large regions of the lung over the course of hours.
People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems.
The European Medicines Agency gave its backing to 15 new medicines at its December meeting, taking its total for the year to 96.